Company news

Anavex Life Sciences Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

August 4, 2025

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

July 30, 2025

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 12, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 5, 2025

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

April 30, 2025

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

April 29, 2025

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

April 22, 2025

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

April 20, 2025

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

April 4, 2025

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

March 30, 2025

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

February 23, 2025

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

February 11, 2025

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

February 4, 2025

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

January 26, 2025

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

January 14, 2025

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

January 12, 2025

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

December 22, 2024

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

December 22, 2024

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

December 15, 2024

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

December 8, 2024

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

December 1, 2024

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

November 25, 2024

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

November 24, 2024

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

October 30, 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

October 16, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

September 2, 2024

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

August 5, 2024

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

July 31, 2024

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

July 29, 2024

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

July 27, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

June 19, 2024

Anavex Life Sciences Announces Expansion of Leadership Team

May 21, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

May 13, 2024

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

May 8, 2024

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

May 1, 2024

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

April 10, 2024

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 24, 2024

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

March 17, 2024

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

February 25, 2024

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

February 6, 2024

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

January 31, 2024

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

January 23, 2024

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

January 15, 2024

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

January 7, 2024

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Anavex Life Sciences Provides an Update on Rett Syndrome Program

January 1, 2024

Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome

December 19, 2023

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease

December 18, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.